GSC
ORMP icon

Ground Swell Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Ground Swell Capital’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-901
Closed -$9K – 2659
2014
Q2 		$9K Buy
+901
New +$9.2K 0.02% 792

Other funds holding ORMP

AWMDMG
Austin W. Marxe & David M. Greenhouse New York $733M AUM 21.72% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Greylin Investment Management Orange, Virginia $598M AUM 18.59% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
U
UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

Ground Swell Capital's ORMP Position: Q3 2014 in Review

Ground Swell Capital sold out of Oramed Pharmaceuticals (ORMP) in Q3 2014, closing a stake of 901 shares — an estimated $9K sold.

Ground Swell Capital first reported a position in ORMP in Q2 2014 and held it in 1 quarter. The position peaked at $9K in Q2 2014. 19 funds tracked by Wall St. Rank hold ORMP as of Q3 2014.

  • Ground Swell Capital reported no remaining Oramed Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Ground Swell Capital sold 901 Oramed Pharmaceuticals shares in Q3 2014, an estimated $9K.
  • Ground Swell Capital first reported a position in Oramed Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Ground Swell Capital's Oramed Pharmaceuticals position peaked at $9K in Q2 2014.
  • 19 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2014.

Based on Ground Swell Capital's 13F filing for Q3 2014, filed 6 Nov 2014.